However, HER2 specificity makes R-115 applicable only in HER2-expressing tumors, such as mammary tumors, and merely suitable for the treatment of other lethal cancers, such as glioblastoma or other non-HER2-expressing tumors [90]. The gene discussed is ERBB2; the disease is glioblastoma.